All articles by Elliot Gardner

Elliot Gardner

Unreal Engine: from gaming to ground-breaking cures

Drug development company C4X Discovery is using the same technology used to build the incredibly popular Fortnite video game to develop medicines in the digital world that it hopes can make an impact in the real world. But, why a gaming engine, and how does it work? Elliot Gardner finds out more.

Hereditary Alzheimer’s: could rare genes hold the key to a cure?

Those living with dominantly inherited Alzheimer’s disease (DIAD) make up less than 1% of the Alzheimer’s population, but the genes of these individuals could provide a deeper understanding of the disease a whole. Elliot Gardner finds out more about DIAD and the efforts of the Dominantly Inherited Alzheimer Network.

Could digital tech unlock billions in savings for pharma companies?

A new Accenture study projects a potential £22bn in cost savings in the UK pharmaceuticals industry through investment in digital technology. With patient screening, data analytics and wearable technology touted as exciting burgeoning areas within the pharma space, Elliot Gardner speaks to Accenture analysts to find out more.

Tracing the story of mumps: a timeline

A recent resurgence of mumps in the US has been linked to a waning effect of the vaccines normally used to create immunity. Elliot Gardner takes a closer look at the history of mumps and the drugs used to treat the disease.

Award-winning pharma packaging

Pharmapack Europe has revealed the winners of the 2018 Pharmapack Awards. Elliot Gardner profiles the six winning packaging systems, from a motor-driven disposable auto-injector to an all-in-one contactless multidose delivery cap.

Hemophilia B gene therapy race heats up following Fitusiran’s failure

Removing the need for a regular infusion of the missing Factor IX (FIX) is a long-term goal for the treatment of hemophilia B.

US drug imports: a recipe for disaster?

With US prescription drug prices among the highest in the world, legislation has been proposed that would allow cheaper foreign imports. However, opponents say this would undermine supply chain security and compromise drug quality. Abi Millar explores both sides of the debate.

The gene-silencing approach to cutting cholesterol

The Medicine Company’s inclisiran, which is moving into phase III clinical trials, could halve cholesterol in patients at high risk of cardiovascular disease. Unlike all previous treatments, it works by ‘switching off’ one of the genes responsible for high cholesterol levels. Abi Millar profiles this new approach to tackling one of the world’s most persistent public health issues.

Pooling resources for clinical trials

Adaptive clinical trial models, which allow researchers to tweak and change a trial as it progresses, are becoming more and more popular. But are pharma companies willing to make the changes to both infrastructure and mind-set to allow for more flexible protocols? Abi Millar finds out.

Alzheimer’s drugs: will 2017 bring better news?

No new Alzheimer’s drug has won approval since 2003, but the tide could soon start turning for this previously poorly understood disease. Elly Earls talks to the field’s top researchers to find out what we can expect over the next few years.